Detecting oral kallikrein-targeting therapy through triggered contact activation: a phase I study.

Zonne L. M. Hofman,Chantal C Clark,C. Erik Hack,Steven de Maat,Coen Maas

Detecting oral kallikrein-targeting therapy through triggered contact activation: a phase I study.

2020

Zonne L. M. Hofman
Chantal C Clark
C. Erik Hack
Steven de Maat
Coen Maas

CAPSULE SUMMARY: The oral kallikrein inhibitor ATN-249 is a candidate therapy for hereditary angioedema. We demonstrate the biological activity of this compound in plasma samples from a phase I study through investigation of ex vivo triggered contact activation.

Keywords:

Ex vivo
Kallikrein
Bradykinin
contact activation
Immunology
Hereditary angioedema
Capsule
Pharmacology
Medicine
Biological activity
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations